Global Microscopic Polyangiitis (MPA) Treatment Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01256337

Publication Date:

January 16, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Microscopic Polyangiitis (MPA) Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淢icroscopic Polyangiitis (MPA) Treatment Industry Forecast鈥� looks at past sales and reviews total world Microscopic Polyangiitis (MPA) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Microscopic Polyangiitis (MPA) Treatment sales for 2025 through 2031. With Microscopic Polyangiitis (MPA) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Microscopic Polyangiitis (MPA) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Microscopic Polyangiitis (MPA) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Microscopic Polyangiitis (MPA) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Microscopic Polyangiitis (MPA) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microscopic Polyangiitis (MPA) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Microscopic Polyangiitis (MPA) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Microscopic Polyangiitis (MPA) Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Avacopan
Immune Globulin
Rituximab Biosimilar
Others
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Celltrion Inc
ChemoCentryx Inc
Sandoz International GmbH
Teijin Pharma Ltd
TTY Biopharm Company Ltd

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Microscopic Polyangiitis (MPA) Treatment Market Size (2020-2031)
2.1.2 Microscopic Polyangiitis (MPA) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Microscopic Polyangiitis (MPA) Treatment by Country/Region (2020, 2024 & 2031)
2.2 Microscopic Polyangiitis (MPA) Treatment Segment by Type
2.2.1 Avacopan
2.2.2 Immune Globulin
2.2.3 Rituximab Biosimilar
2.2.4 Others
2.3 Microscopic Polyangiitis (MPA) Treatment Market Size by Type
2.3.1 Microscopic Polyangiitis (MPA) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Microscopic Polyangiitis (MPA) Treatment Market Size Market Share by Type (2020-2025)
2.4 Microscopic Polyangiitis (MPA) Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Microscopic Polyangiitis (MPA) Treatment Market Size by Application
2.5.1 Microscopic Polyangiitis (MPA) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Microscopic Polyangiitis (MPA) Treatment Market Size Market Share by Application (2020-2025)
3 Microscopic Polyangiitis (MPA) Treatment Market Size by Player
3.1 Microscopic Polyangiitis (MPA) Treatment Market Size Market Share by Player
3.1.1 Global Microscopic Polyangiitis (MPA) Treatment Revenue by Player (2020-2025)
3.1.2 Global Microscopic Polyangiitis (MPA) Treatment Revenue Market Share by Player (2020-2025)
3.2 Global Microscopic Polyangiitis (MPA) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Microscopic Polyangiitis (MPA) Treatment by Region
4.1 Microscopic Polyangiitis (MPA) Treatment Market Size by Region (2020-2025)
4.2 Global Microscopic Polyangiitis (MPA) Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Microscopic Polyangiitis (MPA) Treatment Market Size Growth (2020-2025)
4.4 APAC Microscopic Polyangiitis (MPA) Treatment Market Size Growth (2020-2025)
4.5 Europe Microscopic Polyangiitis (MPA) Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment Market Size Growth (2020-2025)
5 Americas
5.1 Americas Microscopic Polyangiitis (MPA) Treatment Market Size by Country (2020-2025)
5.2 Americas Microscopic Polyangiitis (MPA) Treatment Market Size by Type (2020-2025)
5.3 Americas Microscopic Polyangiitis (MPA) Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Microscopic Polyangiitis (MPA) Treatment Market Size by Region (2020-2025)
6.2 APAC Microscopic Polyangiitis (MPA) Treatment Market Size by Type (2020-2025)
6.3 APAC Microscopic Polyangiitis (MPA) Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Microscopic Polyangiitis (MPA) Treatment Market Size by Country (2020-2025)
7.2 Europe Microscopic Polyangiitis (MPA) Treatment Market Size by Type (2020-2025)
7.3 Europe Microscopic Polyangiitis (MPA) Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment by Region (2020-2025)
8.2 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Microscopic Polyangiitis (MPA) Treatment Market Forecast
10.1 Global Microscopic Polyangiitis (MPA) Treatment Forecast by Region (2026-2031)
10.1.1 Global Microscopic Polyangiitis (MPA) Treatment Forecast by Region (2026-2031)
10.1.2 Americas Microscopic Polyangiitis (MPA) Treatment Forecast
10.1.3 APAC Microscopic Polyangiitis (MPA) Treatment Forecast
10.1.4 Europe Microscopic Polyangiitis (MPA) Treatment Forecast
10.1.5 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment Forecast
10.2 Americas Microscopic Polyangiitis (MPA) Treatment Forecast by Country (2026-2031)
10.2.1 United States Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.2.2 Canada Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.2.3 Mexico Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.2.4 Brazil Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.3 APAC Microscopic Polyangiitis (MPA) Treatment Forecast by Region (2026-2031)
10.3.1 China Microscopic Polyangiitis (MPA) Treatment Market Forecast
10.3.2 Japan Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.3.3 Korea Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.3.4 Southeast Asia Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.3.5 India Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.3.6 Australia Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.4 Europe Microscopic Polyangiitis (MPA) Treatment Forecast by Country (2026-2031)
10.4.1 Germany Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.4.2 France Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.4.3 UK Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.4.4 Italy Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.4.5 Russia Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.5 Middle East & Africa Microscopic Polyangiitis (MPA) Treatment Forecast by Region (2026-2031)
10.5.1 Egypt Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.5.2 South Africa Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.5.3 Israel Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.5.4 Turkey Market Microscopic Polyangiitis (MPA) Treatment Forecast
10.6 Global Microscopic Polyangiitis (MPA) Treatment Forecast by Type (2026-2031)
10.7 Global Microscopic Polyangiitis (MPA) Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Microscopic Polyangiitis (MPA) Treatment Forecast
11 Key Players Analysis
11.1 Celltrion Inc
11.1.1 Celltrion Inc Company Information
11.1.2 Celltrion Inc Microscopic Polyangiitis (MPA) Treatment Product Offered
11.1.3 Celltrion Inc Microscopic Polyangiitis (MPA) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Celltrion Inc Main Business Overview
11.1.5 Celltrion Inc Latest Developments
11.2 ChemoCentryx Inc
11.2.1 ChemoCentryx Inc Company Information
11.2.2 ChemoCentryx Inc Microscopic Polyangiitis (MPA) Treatment Product Offered
11.2.3 ChemoCentryx Inc Microscopic Polyangiitis (MPA) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 ChemoCentryx Inc Main Business Overview
11.2.5 ChemoCentryx Inc Latest Developments
11.3 Sandoz International GmbH
11.3.1 Sandoz International GmbH Company Information
11.3.2 Sandoz International GmbH Microscopic Polyangiitis (MPA) Treatment Product Offered
11.3.3 Sandoz International GmbH Microscopic Polyangiitis (MPA) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Sandoz International GmbH Main Business Overview
11.3.5 Sandoz International GmbH Latest Developments
11.4 Teijin Pharma Ltd
11.4.1 Teijin Pharma Ltd Company Information
11.4.2 Teijin Pharma Ltd Microscopic Polyangiitis (MPA) Treatment Product Offered
11.4.3 Teijin Pharma Ltd Microscopic Polyangiitis (MPA) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Teijin Pharma Ltd Main Business Overview
11.4.5 Teijin Pharma Ltd Latest Developments
11.5 TTY Biopharm Company Ltd
11.5.1 TTY Biopharm Company Ltd Company Information
11.5.2 TTY Biopharm Company Ltd Microscopic Polyangiitis (MPA) Treatment Product Offered
11.5.3 TTY Biopharm Company Ltd Microscopic Polyangiitis (MPA) Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 TTY Biopharm Company Ltd Main Business Overview
11.5.5 TTY Biopharm Company Ltd Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂